British Journal of Haematology最新文献

A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study. IFM 2018-02 II期研究结果：无地塞米松daratumumab-ixazomib方案治疗复发或难治性多发性骨髓瘤的虚弱老年患者

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-07 DOI: 10.1111/bjh.70512

Arthur Bobin, Margaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulman, Caroline Lenoir, Pascal Godmer, Jean-Jacques Parienti, Laure Peyro Saint Paul, Anaïs Briant, Xavier Leleu

{"title":"A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study.","authors":"Arthur Bobin, Margaret Macro, Cyrille Touzeau, Clara Mariette, Salomon Manier, Sabine Brechignac, Laure Vincent, Benjamin Hebraud, Olivier Decaux, Samantha Schulman, Caroline Lenoir, Pascal Godmer, Jean-Jacques Parienti, Laure Peyro Saint Paul, Anaïs Briant, Xavier Leleu","doi":"10.1111/bjh.70512","DOIUrl":"https://doi.org/10.1111/bjh.70512","url":null,"abstract":"The combination of CD38 immunotherapy and proteasome inhibition has shown synergistic activity. Elderly relapsed or refractory multiple myeloma (RRMM) experience worse outcomes due to variabilities in fitness and higher rates of adverse events (AEs) and treatment discontinuations. The Intergroupe Francophone du Myélome (IFM) 2018-02 trial (NCT03757221) evaluated a dexamethasone-free regimen of daratumumab and ixazomib (I-Dara) in elderly frail RRMM. This prospective, phase 2 trial was conducted at 14 IFM centres. Patients aged ≥65 years with International Myeloma Working Group frailty score ≥2 and an Eastern Cooperative Oncology Group 0-2 in first or second relapse received daratumumab 16 mg/kg; ixazomib 4 mg weekly d1, d8, d15 in a 28-day cycle; and methylprednisolone. The primary end-point was ≥ very good partial response (VGPR) rate. Of 55 patients included, the median age was 82 years, with 90% aged over 75. VGPR or better was 32%. With a median follow-up of 35.3 months, the median progression-free survival time was 19.5 months. The median OS was not reached: 75% at 33.6 months. Grade ≥3 AEs occurred in 36 (67%) patients: cytopenias in 18 and infection in 8 (6 pneumonia). The IFM 2018-02 shows that I-Dara demonstrated an acceptable safety profile for this elderly frail RRMM patients' population. The response rates and survival outcomes were acceptable given the studied population.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statistical considerations in the comparison of immunotherapy and chemotherapy for POD24 follicular lymphoma. POD24滤泡性淋巴瘤免疫治疗与化疗比较的统计学考虑。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-07 DOI: 10.1111/bjh.70522

Can Yan, Jinlin Liu

引用次数: 0

Comments on 'Dose-dependent impairment of brain functional and microstructural connectivity during leukaemia chemotherapy'. 对“白血病化疗期间脑功能和微结构连通性的剂量依赖性损伤”的评论。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-07 DOI: 10.1111/bjh.70537

Jinlin Liu

引用次数: 0

An atypical bilobed and binucleated splenic marginal zone lymphoma. 不典型双叶双核脾边缘区淋巴瘤。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-07 DOI: 10.1111/bjh.70514

Quentin Amiot, Anne-Margaux Legland Ép Dejean, Jean-Christian Navarrot, Pierre Arnautou, Jean-Valère Malfuson, Carine Hejl

引用次数: 0

Early diagnosis of AL amyloidosis in haematology, cardiology, neurology, renal and general clinics: A British Society for Haematology Guideline. 血液学、心脏病学、神经学、肾脏和普通临床AL淀粉样变的早期诊断：英国血液学学会指南。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-07 DOI: 10.1111/bjh.70472

Mamta Garg, Satarupa Choudhuri, Christopher Parrish, Stephen Hawkins, Helen Lachmann, Louise Clayton, Judith Richardson, Y L Tracey Chan, Ashutosh Wechalekar

引用次数: 0

High frequency of CD95⁺/CD45RA^- regulatory T cells defines an immunosuppressive profile associated with MDS progression. CD95+/CD45RA调节性T细胞的高频率定义了与MDS进展相关的免疫抑制谱。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-04 DOI: 10.1111/bjh.70504

Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis

{"title":"High frequency of CD95+/CD45RA- regulatory T cells defines an immunosuppressive profile associated with MDS progression.","authors":"Romain Vazquez, Nicolas Deredec, Ismael Boussaid, Pierre Boncoeur, Camille Knosp, Amandine Houvert, Loria Zalmai, Chloe Friedrich, Carole Almire, Charles Dussiau, Lise Willems, Rudy Birsen, Justine Decroocq, Didier Bouscary, Olivier Kosmider, Shahram Kordasti, Michaela Fontenay, Yannick Simoni, Nicolas Chapuis","doi":"10.1111/bjh.70504","DOIUrl":"https://doi.org/10.1111/bjh.70504","url":null,"abstract":"Dynamic interactions between mutated haematopoietic cells and immune cells are key drivers of myelodysplastic neoplasms (MDS) initiation and progression. Regulatory T cells (Tregs) are central mediators of immunosuppression in MDS. We thus aimed to characterize Treg subpopulations in the bone marrow (BM) of MDS patients and to explore their clinical significance. Using mass cytometry and an unbiased multidimensional analytical approach, we first confirmed the presence in MDS BM of two Treg subsets, including the highly activated CD95+/CD45RA- subpopulation previously reported in aplastic anaemia. We then prospectively analysed Tregs distribution in BM of 113 MDS patients at diagnosis and during follow-up. While Treg proportions among CD4+ T cells were unchanged, CD95+/CD45RA- Tregs were significantly expanded in the BM of both low- and high-risk MDS patients. CD95+/CD45RA- Tregs accumulated during disease evolution but remained stable in patients responding to hypomethylating agents. At diagnosis, CD95+/CD45RA- Tregs levels correlated with specific clinical features: low CD95+/CD45RA- Tregs with TET2/IDH mutations and autoimmune manifestations; high CD95+/CD45RA- Tregs with an increased risk of disease progression independently of the IPSS-R and the IPSS-M. Our findings suggest that profiling Treg subpopulations at diagnosis could improve MDS risk stratification and guide immunosuppressive therapeutic decisions.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of thromboembolism in patients with metastatic renal cell carcinoma treated with combination-based immunotherapy. 联合免疫治疗转移性肾细胞癌患者血栓栓塞的风险

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-03 DOI: 10.1111/bjh.70526

Yu-Cheng Chang, Hao-Kuen Lin, Joseph Piwowarski, Yu-Che Lee, Chun-Yu Peng, Wenli Gao, Cho-Han Chiang

引用次数: 0

Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis. 5岁以下和20岁以下儿童镰状细胞性贫血的当代全球负担：系统回顾和荟萃分析。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-03 DOI: 10.1111/bjh.70501

Kelly Pimenta, Jeffrey Edwards, Meredith Ray, Abu Mohd Naser, Carrie Price, Ombeni Idassi, Kathleen Strong, Wilson Were, Frédéric B Piel, Jane S Hankins, Matthew Smeltzer

{"title":"Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.","authors":"Kelly Pimenta, Jeffrey Edwards, Meredith Ray, Abu Mohd Naser, Carrie Price, Ombeni Idassi, Kathleen Strong, Wilson Were, Frédéric B Piel, Jane S Hankins, Matthew Smeltzer","doi":"10.1111/bjh.70501","DOIUrl":"https://doi.org/10.1111/bjh.70501","url":null,"abstract":"Sickle cell disease (SCD), a prevalent inherited non-communicable disease, remains a neglected public health priority, especially children and adolescents in many low- and middle-income countries. The global burden of SCD in youth remains under-characterized given fragmented data and disparities in diagnostics. This study aims to conduct a systematic review and meta-analysis quantifying the global prevalence and cause-specific mortality of SCD in individuals aged under-5 and under-20. A search was conducted to identify studies reporting SCD prevalence or mortality published between 2017 and 2023. Eligible studies were assessed for quality and random-effects meta-analyses generated pooled estimates, stratified by age group, study design and United Nations country group classification. Fifty-seven studies were included, encompassing data from over 3.6 million individuals and 56 593 recorded deaths. Among children under-5, the prevalence was 0.008 (95% confidence interval [CI]: 0.004-0.016). The global under-20 population-based prevalence of SCD was 0.009 (95% CI: 0.005-0.017). The global under-20 cause-specific mortality proportion was 0.029 (95% CI: 0.001-0.621), with under-5 and 5-19 years of age mortality proportions estimated at 0.021 and 0.017, respectively. This first global synthesis of under-5s and under-20s demonstrates substantial paediatric burden but is constrained by extreme heterogeneity, wide uncertainty and incomplete geographic coverage, underscoring the urgency for improved screening, surveillance and cause-of-death attribution to support accurate global burden estimation of SCD.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom. 加速期和胚期骨髓增生性肿瘤的现实治疗模式和结果：来自英国一项大型多中心队列分析的见解。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-03 DOI: 10.1111/bjh.70511

Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C P Somervaille, Donal P McLornan

{"title":"Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.","authors":"Alexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, Ahmad Alabdulkarim, Jennifer Ryan, Frances Wadelin, Samah Alimam, Phyo Wint Wint Tun, Jonathan Lambert, Jennifer O'Sullivan, Andrew J Wilson, Laith Tafesh, Andrew McGregor, Simone Claudiani, Andrew Innes, Emily Booth, James Leveson, Steve Knapper, Mamta Garg, Mani Dubey, Theodora Vatopoulou, Charlotte Brierley, Wai Ka Natalie Leung, Graham Greenfield, Mary Frances McMullin, Alesia Khan, Kate Milne, Duncan Brian, Anna Godfrey, Claire N Harrison, Bethan Psaila, Patrick Harrington, Amy Kirkwood, Tim C P Somervaille, Donal P McLornan","doi":"10.1111/bjh.70511","DOIUrl":"https://doi.org/10.1111/bjh.70511","url":null,"abstract":"This UK-based retrospective analysis describes real-world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast-phase (BP, n = 106) 'Philadelphia-negative' myeloproliferative neoplasms (MPN-AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years. With a median follow-up of 45.2 months, median overall survival (OS) was 14.9 months, significantly worse for MPN-BP (6.7 months) versus MPN-AP (25.3 months). Treatment selection was heterogeneous across centres. Intensive chemotherapy (IC) improved outcomes only when followed by allogeneic haematopoietic stem cell transplant (allo-HSCT) (median OS 24.7 months). Ruxolitinib-based regimens, particularly combined with azacitidine, showed acceptable activity in AP (median OS 27.2 months). Venetoclax-based regimens achieved a median OS of 14.9 months across the cohort. Multivariable analysis identified IC and venetoclax-based therapy as independently associated with better outcomes, reflecting patient selection, while TP53 mutations predicted inferior survival. IC carried high rates of febrile neutropenia and sepsis; venetoclax was associated with prolonged cytopenias. This study confirms the poor prognosis of MPN-AP/BP, the absence of a unified UK consensus approach and the need for improved therapies and prospective studies to determine optimal treatment approaches for this challenging cohort.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia. 综合蛋白质组学和代谢组学分析揭示了性别分层的生物标志物预测儿童原发性免疫性血小板减少症的慢性性。

IF 3.8 2区医学

British Journal of Haematology Pub Date : 2026-05-03 DOI: 10.1111/bjh.70521

Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan

{"title":"Integrated proteomic and metabolomic profiling reveals sex-stratified biomarkers predicting chronicity in paediatric primary immune thrombocytopenia.","authors":"Yuanyuan Xue, Rongrong Zhang, Dongmei Liang, Yupeng Xu, Zhaofang Tian, Xiaohong Dai, Wei Xu, Qingqing Cao, Haiyan Zhu, Yun Wang, Yufang Yuan","doi":"10.1111/bjh.70521","DOIUrl":"https://doi.org/10.1111/bjh.70521","url":null,"abstract":"This study aimed to develop prediction models for chronic immune thrombocytopenia (ITP) using a sex-stratified proteomic and metabolomic approach, providing a framework for individualized prognosis evaluation and timely clinical management. This investigation was designed as a non-interventional, prospective observational cohort. Plasma samples were collected from 67 children initially diagnosed with ITP along with 40 healthy controls. After a minimum of 1 year of regular follow-up, participants were classified according to sex and disease progression. The male and female cohorts each comprised individuals with chronic ITP, non-chronic ITP and healthy controls. From each subgroup, three peripheral blood samples were randomly chosen for proteomic and metabolomic profiling. Integrative omics were analysed for correlations using Pearson's coefficient (threshold: |r| > 0.8, p < 0.05). Predictive models were constructed using sex-specific biomarkers associated with chronic progression. The analysis identified intercellular adhesion molecule-1 (ICAM-1) and biopterin in males and actin, alpha 2, smooth muscle, aorta (ACTA-2) and N6-acetyl-L-lysine in females as associated factors. Cross-sex applications of these biomarkers revealed limited predictive value. Furthermore, the receiver operating characteristics curves, calibration curves and clinical decision curve analysis demonstrated good predictive efficacy of these predictive models. The underlying mechanisms of interaction between these biomarkers, sex differences and ITP chronicity progression warrant further investigation.","PeriodicalId":135,"journal":{"name":"British Journal of Haematology","volume":" ","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147808968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0